Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism

• Published in: Journal of the American Geriatrics Society (JAGS) Vol. 66; no. 3; pp. 518 - 524
• Main Authors: Eller‐Vainicher, Cristina, Palmieri, Serena, Cairoli, Elisa, Goggi, Giovanni, Scillitani, Alfredo, Arosio, Maura, Falchetti, Alberto, Chiodini, Iacopo
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2018
• Subjects: Absorptiometry; Alkaline phosphatase; Body mass index; Bone mass; Bone mineral density; Calcium metabolism; denosumab; Drug therapy; Femur; Fractures; fragility fractures; Geriatrics; Hip; Hyperparathyroidism; Immunotherapy; Monoclonal antibodies; Older people; Osteoporosis; Phosphorus; primary hyperparathyroidism; Radiography; Spine (lumbar); Vertebrae; bone mineral density; fragility fractures; primary hyperparathyroidism; denosumab

Objectives To determine the effect of denosumab, which is used in primary osteoporosis (PO), in primary hyperparathyroidism (PHPT)‐related osteoporosis. Design Retrospective, longitudinal study. Setting Outpatient osteoporosis clinic. Participants Older women with PHPT (78.6 ± 5.5) (n = 25) and PO (...